Niagen. BIOSCIENCE

NEWS RELEASE

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

2026-10-08

This award recognizes Dr. Shao's dedication to advancing NAD+ research and scientific excellence responsibly within the dietary supplement industry

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the **2026 Annette Dickinson Trailblazer Award**.

Radicle Science Co-founder and CEO Jeff Chen with Andrew Shao, SVP, Global Scientific and Regulatory Affairs, Niagen Bioscience, Radicle Science Co-founder and Executive Chair Pelin Thorogood, and CRN President & CEO Steve Mister.

"This award is incredibly special to me because I had the privilege of working alongside Annette for many years, and that experience has had a lasting impact both on me personally and my career," said Dr. Shao. "Throughout my career, I have had the opportunity to work with talented scientists, regulators, colleagues, and industry leaders who share a commitment to rigorous science and responsible innovation. I am grateful for this recognition and for the opportunity to continue contributing to an industry that has such potential to improve health and well-being."

The Annette Dickinson Trailblazer Award recognizes leaders whose innovation, advocacy, mentorship, and vision have helped move the dietary supplement and functional food industry forward. The award also honors the lasting legacy of Annette Dickinson, Ph.D., CRN's founding staff member and former president. Dr. Dickinson's leadership helped shape the responsible dietary supplement industry, and her career was defined by science, advocacy, and service.

"Dr. Shao's career reflects the kind of leadership Annette Dickinson embodied: the ability and willingness to do the hard work of building stronger science, stronger standards, and stronger connections across the industry," said Gretchen Powers, CRN vice president, marketing and member experience. "His influence reaches well beyond any one role or organization, and CRN is proud to recognize the lasting contribution he has made to our community and to the field."

Before joining Niagen Bioscience, Dr. Shao held scientific and regulatory leadership roles at multinational companies and trade associations, including Herbalife Nutrition, and the Council for Responsible Nutrition (CRN). Dr. Dickinson hired Dr. Shao as Vice President of Scientific and Regulatory Affairs at CRN, and that six-year experience shaped a career advising governments globally on science-based regulatory and policy reform, addressing topics from health claims and risk analysis to botanical regulations.

"Dr. Shao has spent his career pushing the boundaries of what is possible in evidence-based wellness, bringing scientific rigor, curiosity, and a spirit of collaboration to everything he does," said Pelin Thorogood, co-founder and executive chair of Radicle Science. "He understands that rigorous science isn't a barrier to innovation—it's what makes meaningful innovation possible. His leadership has helped advance our industry and bring us closer to a future where wellness is not just promising, but proven. That is the spirit of a true trailblazer."

For additional information on Niagen Bioscience leadership, visit **www.niagenbioscience.com**.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at **www.truniagen.com**), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (**www.niagenplus.com**). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at **www.niagenbioscience.com**, where copies of press releases, news, and financial information are regularly published.

† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends" "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, statements regarding Niagen Bioscience's NB4168 pharmaceutical development program; planned preclinical, IND-enabling and clinical development activities; the potential timing of an IND submission or first-in-human study; the potential bioavailability, exposure, safety, tolerability, efficacy, pharmacodynamic or clinical profile of NB4168; and the Company's ability to translate its NAD+ platform into pharmaceutical products; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-

party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Niagen@kcsa.com

Source: Niagen Bioscience, Inc